Datapoint: FDA Approves TG Therapeutics’ MS Antibody Briumvi
The FDA on Dec. 28 approved TG Therapeutics, Inc.’s Briumvi for the treatment of relapsing forms of multiple sclerosis. The monoclonal antibody will be the third anti-CD20 therapy in the relapsing MS market basket, joining Roche’s Ocrevus and Novartis’ Kesimpta. Briumvi boasts a novel administration, however — a one-hour infusion every six months following its four-hour starting dose. For the treatment of MS, Ocrevus holds covered or better status for 66% of all insured lives under the pharmacy benefit and 92% of lives under the medical benefit. Kesimpta, meanwhile, holds covered or better status for 85% of insured lives under the pharmacy benefit, and 13% of lives under the medical benefit.
SOURCE: MMIT Analytics, as of 1/9/23